Well, at least we have a biotech deal. I will discuss it but I am not sure this is the deal the sector was hoping for and probably does not alter sentiment to a large degree. We still have a lot of catalysts coming and perhaps this deal is just the start of more to […]
The CNST Bull Case in a Single Slide
Constellation Pharmaceuticals presented some compelling data at ASH. In early results from 15 JAKi naive Myelofibrosis patients treated with a combination of BET inhibitor CPI-0610 and ruxolitinib, 12 (80%) achieved a Spleen Volume Response of at least 35% (SVR35). The numbers indicate 8/11 (73%) of the newly added patients had a response. This is a […]
December 10 Biotech Update
It seems like the sector might breakout and run yesterday morning but it came back to reality in the afternoon. While it would have been nice to see a run, the pullback does not change the trend. Perhaps we will now see a little weakness and pullback to higher lows (as had been the case) […]
Taking a BET on CNST
Constellation Pharmaceuticals is focused on the development of cancer therapeutics by targeting the epigenetic pathway. It has EZH2 and BET inhibitors in mid-stage clinical studies. Excitement in the stock is driven by the BET inhibitor CPI-0610. There is substantial interest in this class of compounds. While small biotechs often lead the way with novel targets, […]
